Tafluprost/timolol

Drug Profile

Tafluprost/timolol

Alternative Names: DE-111; Tafluprost/timolol maleate; TAPCOM; Taptiqom; Timolol maleate/tafluprost; Timolol/tafluprost

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Santen Oy; Santen Pharmaceutical
  • Developer Asahi Glass; Santen Oy; Santen Pharmaceutical
  • Class Amino alcohols; Antiglaucomas; Antihypertensives; Ischaemic heart disorder therapies; Morpholines; Propanolamines; Prostaglandins; Small molecules; Thiadiazoles
  • Mechanism of Action Beta-adrenergic receptor antagonists; Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Glaucoma; Ocular hypertension

Most Recent Events

  • 01 Dec 2016 Santen Pharmaceutical completes a phase II trial for Open angle glaucoma and Ocular hypertension in Japan (Ophthalmic) (UMIN000016052)
  • 09 Sep 2016 Launched for Ocular hypertension and Glaucoma in Estonia (Ophthalmic) before September 2016
  • 10 Aug 2016 Santen Pharmaceutical initiates a clinical trial for Open angle glaucoma in Japan (Ophthalmic) (UMIN000023883)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top